Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Fifteen-year experience with renal cell carcinoma with associated venous tumor thrombus.

Nooromid MJ, Ju MH, Havelka GE, Kozlowski JM, Kundu SD, Eskandari MK.

Surgery. 2016 Oct;160(4):915-923. doi: 10.1016/j.surg.2016.06.029. Epub 2016 Aug 6.

PMID:
27506867
2.

Vitamin D deficiency predicts prostate biopsy outcomes.

Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, Nadler RB, Kozlowski JM, Perry KT, Kajdacsy-Balla A, Kittles R.

Clin Cancer Res. 2014 May 1;20(9):2289-99. doi: 10.1158/1078-0432.CCR-13-3085.

3.

Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.

Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C.

Urology. 2010 Dec;76(6):1519.e8-13. doi: 10.1016/j.urology.2010.03.061. Epub 2010 Oct 27.

4.

Vena cava thrombectomy and primary repair after radical nephrectomy for renal cell carcinoma: single-center experience.

Helfand BT, Smith ND, Kozlowski JM, Eskandari MK.

Ann Vasc Surg. 2011 Jan;25(1):39-43. doi: 10.1016/j.avsg.2010.05.020.

PMID:
20889305
5.

Differentiation, self-other representations, and rupture-repair processes: predicting child maltreatment-risk.

Skowron EA, Kozlowski JM, Pincus AL.

J Couns Psychol. 2010 Jul;57(3):304-316. doi: 10.1037/a0020030.

6.

17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells.

Park II, Zhang Q, Liu V, Kozlowski JM, Zhang J, Lee C.

Endocrinology. 2009 Oct;150(10):4594-605. doi: 10.1210/en.2008-1591. Epub 2009 Jul 16.

PMID:
19608654
7.

Intra-operative pubic arch interference during prostate seed brachytherapy in patients with CT-based pubic arch interference of < or =1cm.

Sejpal SV, Sathiaseelan V, Helenowski IB, Kozlowski JM, Carter MF, Nadler RB, Dalton DP, McVary KT, Lin WW, Garnett JE, Kalapurakal JA.

Radiother Oncol. 2009 May;91(2):249-54. doi: 10.1016/j.radonc.2009.02.006. Epub 2009 Mar 9.

PMID:
19272664
8.

Topoisomerase II alpha expression in testicular germ cell tumors.

Dimov ND, Zynger DL, Luan C, Kozlowski JM, Yang XJ.

Urology. 2007 May;69(5):955-61.

PMID:
17482942
9.

Implications of therapy choice on overall survival in metastatic renal cell carcinoma: a single institution experience.

Parmar S, Rademaker AW, Fung BB, Kozlowski JM, Kuzel TM.

Med Oncol. 2005;22(4):399-405.

PMID:
16260858
10.

Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.

Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C.

Prostate Cancer Prostatic Dis. 2004;7(3):243-8.

11.

Pigment epithelium-derived factor, a human testis epididymis secretory product, promotes human prostate stromal cell growth in culture.

Grayhack JT, Smith ND, Ilio K, Wambi C, Kasjanski R, Crawford SE, Doll JA, Wang Z, Lee C, Kozlowski JM.

J Urol. 2004 Jan;171(1):434-8.

PMID:
14665949
12.

Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-beta1.

Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, Zhang J, Lee C, Ilio K.

Endocrinology. 2003 Oct;144(10):4280-4. Epub 2003 Jul 24.

13.

Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer.

Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z.

Cancer Res. 2003 Aug 1;63(15):4698-704.

14.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM.

J Urol. 2003 Apr;169(4):1219-28. Review.

PMID:
12629332
15.

Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo.

Abasolo I, Yang L, Haleem R, Xiao W, Pio R, Cuttitta F, Montuenga LM, Kozlowski JM, Calvo A, Wang Z.

Mol Cell Endocrinol. 2003 Jan 31;199(1-2):179-87.

PMID:
12581889
16.

High fat diet increases the weight of rat ventral prostate.

Cai X, Haleem R, Oram S, Cyriac J, Jiang F, Grayhack JT, Kozlowski JM, Wang Z.

Prostate. 2001 Sep 15;49(1):1-8.

PMID:
11550205
17.

Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1.

Ilio KY, Park II, Pins MR, Kozlowski JM, Lee C.

Prostate. 2001 Aug 1;48(3):131-5.

PMID:
11494328
18.

NCCN Practice Guidelines for Prostate Cancer.

Bahnson RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M 3rd, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG; National Comprehensive Cancer Network.

Oncology (Williston Park). 2000 Nov;14(11A):111-9.

PMID:
11195405
19.

Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells: role of heparin/heparan-degrading enzymes.

Kassen AE, Sensibar JA, Sintich SM, Pruden SJ, Kozlowski JM, Lee C.

Prostate. 2000 Jul 1;44(2):124-32.

PMID:
10881022
20.

Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin).

Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, Sensibar JA.

Prostate. 1999 May;39(2):87-93.

PMID:
10221563
21.

Differential growth rates in stromal cultures of human prostate derived from patients of varying ages.

Sensibar JA, Pruden SJ, Kasjanski RZ, Rademaker A, Lee C, Grayhack JT, Kozlowski JM.

Prostate. 1999 Feb 1;38(2):110-7.

PMID:
9973096
22.

Acute adrenal insufficiency following unilateral radical nephrectomy: a case report.

Safir MH, Smith N, Hansen L, Kozlowski JM.

Geriatr Nephrol Urol. 1998;8(2):101-2.

PMID:
9893218
23.

The pathogenesis of benign prostatic hyperplasia: a proposed hypothesis and critical evaluation.

Grayhack JT, Kozlowski JM, Lee C.

J Urol. 1998 Dec;160(6 Pt 2):2375-80.

PMID:
9817388
24.

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA.

Clin Cancer Res. 1997 Oct;3(10):1707-11.

25.

Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.

Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, Lee C.

Clin Cancer Res. 1998 Jul;4(7):1625-30.

26.

Synergistic action of steroids and spermatocele fluid on in vitro proliferation of prostate stroma.

Grayhack JT, Sensibar JA, Ilio KY, Kasjanski RZ, Kozlowski JM, Lee C.

J Urol. 1998 Jun;159(6):2202-9.

PMID:
9598570
27.

Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.

Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C.

Br J Cancer. 1998 Mar;77(6):855-61.

28.

Intrinsic and extrinsic factors controlling benign prostatic growth.

Lee C, Kozlowski JM, Grayhack JT.

Prostate. 1997 May 1;31(2):131-8. Review.

PMID:
9140127
29.

Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts.

Williams BJ, Jones E, Kozlowski JM, Vessella R, Brothman AR.

Genes Chromosomes Cancer. 1997 Apr;18(4):299-304.

PMID:
9087570
30.

The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.

Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D.

Prostate. 1996 Sep;29(3):177-82.

PMID:
8827086
31.

Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.

Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C.

Clin Cancer Res. 1996 Aug;2(8):1255-61.

32.

Stromal cells of the human prostate: initial isolation and characterization.

Kassen A, Sutkowski DM, Ahn H, Sensibar JA, Kozlowski JM, Lee C.

Prostate. 1996 Feb;28(2):89-97.

PMID:
8604397
33.

Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin).

Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, Kozlowski JM, Lee C.

Cancer Res. 1995 Jun 1;55(11):2431-7.

34.

Etiology of benign prostatic hyperplasia.

Lee C, Kozlowski JM, Grayhack JT.

Urol Clin North Am. 1995 May;22(2):237-46. Review.

PMID:
7539172
35.

Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.

Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM.

Endocrinology. 1995 Feb;136(2):796-803.

PMID:
7530653
36.
37.

The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.

Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D.

Urology. 1994 Oct;44(4):481-5. Review. No abstract available.

PMID:
7524233
38.

Effect of spermatocele fluid on growth of human prostatic cells in culture.

Sutkowski DM, Kasjanski RZ, Sensibar JA, Ney KG, Lim DJ, Kozlowski JM, Lee C, Grayhack JT.

J Androl. 1993 Jul-Aug;14(4):233-9.

39.

Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.

Fong CJ, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM.

J Urol. 1993 May;149(5):1190-4.

PMID:
7683344
40.

In vivo and in vitro approaches to study metastasis in human prostatic cancer.

Lee C, Shevrin DH, Kozlowski JM.

Cancer Metastasis Rev. 1993 Mar;12(1):21-8. Review.

PMID:
8448823
41.

DNA profile of nephrogenic adenoma assessed by flow cytometry.

Gaylis FD, Keer HN, Bauer KD, Kozlowski JM, Grayhack JT.

Urology. 1993 Feb;41(2):160-1.

PMID:
8497991
42.

Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice.

Lim DJ, Liu XL, Sutkowski DM, Braun EJ, Lee C, Kozlowski JM.

Prostate. 1993;22(2):109-18.

PMID:
7681204
44.

Purtscher's-like retinopathy associated with a cardiac aneurysm.

Kozlowski JM, Peters AL.

Arch Ophthalmol. 1992 Jun;110(6):880-1. No abstract available.

PMID:
1596238
45.

Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate.

Sherwood ER, Fong CJ, Lee C, Kozlowski JM.

Endocrinology. 1992 May;130(5):2955-63.

PMID:
1374018
46.

Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction.

Chang SY, Yu DS, Sherwood ER, Kozlowski JM, Lee C.

J Urol. 1992 Apr;147(4):1147-50.

PMID:
1552613
47.

Chemotherapy.

Kozlowski JM.

J Urol. 1992 Mar;147(3 Pt 2):938-41. No abstract available.

PMID:
1538501
48.

Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture.

Sutkowski DM, Fong CJ, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C.

Prostate. 1992;21(2):133-43.

PMID:
1409120
49.

Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions.

Fong CJ, Sherwood ER, Braun EJ, Berg LA, Lee C, Kozlowski JM.

Prostate. 1992;21(2):121-31.

PMID:
1384014
50.

Supplemental Content

Loading ...
Support Center